Literature DB >> 10103180

Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.

P J Jenks1, A Labigne, R L Ferrero.   

Abstract

The Helicobacter pylori SS1 mouse model was used to characterize the development of resistance in H. pylori after treatment with metronidazole monotherapy and to examine the effect of prior exposure to metronidazole on the efficacy of a metronidazole-containing eradication regimen. Mice colonized with the metronidazole-sensitive H. pylori SS1 strain were treated for 7 days with either peptone trypsin broth or the mouse equivalent of 400 mg of metronidazole once a day or three times per day (TID). In a separate experiment, H. pylori-infected mice were administered either peptone trypsin broth or the mouse equivalent of 400 mg of metronidazole TID for 7 days, followed 1 month later by either peptone trypsin broth or the mouse equivalent of 20 mg of omeprazole, 250 mg of clarithromycin, and 400 mg of metronidazole twice a day for 7 days. At least 1 month after the completion of treatment, the mice were sacrificed and their stomachs were cultured for H. pylori. The susceptibilities of isolates to metronidazole were assessed by agar dilution determination of the MICs. Mixed populations of metronidazole-resistant and -sensitive strains were isolated from 70% of mice treated with 400 mg of metronidazole TID. The ratio of resistant to sensitive strains was 1:100, and the MICs for the resistant strains varied from 8 to 64 micrograms/ml. In the second experiment, H. pylori was eradicated from 70% of mice treated with eradication therapy alone, compared to 25% of mice pretreated with metronidazole (P < 0.01). Mice still infected after treatment with metronidazole and eradication therapy contained mixed populations of metronidazole-resistant and -sensitive isolates in a ratio of 1:25. These results demonstrate that H. pylori readily acquires resistance to metronidazole in vivo and that prior exposure of the organism to metronidazole is associated with failure of eradication therapy. H. pylori-infected mice provide a suitable model for the study of resistance mechanisms in H. pylori and will be useful in determining optimal regimens for the eradication of resistant strains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10103180      PMCID: PMC89206          DOI: 10.1128/AAC.43.4.777

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  The European meeting on Helicobacter pylori: therapeutic news from Lisbon.

Authors:  U Peitz; M Menegatti; D Vaira; P Malfertheiner
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

2.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

3.  In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori.

Authors:  A A van Zwet; J C Thijs; W Schievink-de Vries; J Schiphuis; J A Snijder
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.

Authors:  D Y Graham; G M Lew; P D Klein; D G Evans; D J Evans; Z A Saeed; H M Malaty
Journal:  Ann Intern Med       Date:  1992-05-01       Impact factor: 25.391

5.  The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

Authors:  A M Hirschl; E Hentschel; K Schütze; H Nemec; R Pötzi; A Gangl; W Weiss; M Pletschette; G Stanek; M L Rotter
Journal:  Scand J Gastroenterol Suppl       Date:  1988

6.  Impact of metronidazole resistance on the eradication of Helicobacter pylori.

Authors:  L A Noach; W L Langenberg; M A Bertola; J Dankert; G N Tytgat
Journal:  Scand J Infect Dis       Date:  1994

7.  Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pylori.

Authors:  H Rautelin; W Tee; K Seppälä; T U Kosunen
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

8.  Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.

Authors:  C S Goodwin; B J Marshall; E D Blincow; D H Wilson; S Blackbourn; M Phillips
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

9.  Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

Authors:  G D Bell; K Powell; S M Burridge; A Pallecaros; P H Jones; P W Gant; G Harrison; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

10.  Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

View more
  13 in total

1.  In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori.

Authors:  Sotirios Paraschos; Prokopios Magiatis; Sofia Mitakou; Kalliopi Petraki; Antonios Kalliaropoulos; Petros Maragkoudakis; Andreas Mentis; Dionyssios Sgouras; Alexios-Leandros Skaltsounis
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

Authors:  P J Jenks; R L Ferrero; J Tankovic; J M Thiberge; A Labigne
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori.

Authors:  J Tankovic; D Lamarque; J C Delchier; C J Soussy; A Labigne; P J Jenks
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Differentiation of metronidazole-sensitive and -resistant clinical isolates of Helicobacter pylori by immunoblotting with antisera to the RdxA protein.

Authors:  S R Latham; R J Owen; N C Elviss; A Labigne; P J Jenks
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  Characterization of virulence factors of mouse-adapted Helicobacter pylori strain SS1 and effects on gastric hydrophobicity.

Authors:  A S Day; N L Jones; Z Policova; H A Jennings; E K Yau; P Shannon; A W Neumann; P M Sherman
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

6.  Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole.

Authors:  J Y Jeong; A K Mukhopadhyay; J K Akada; D Dailidiene; P S Hoffman; D E Berg
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

7.  Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori.

Authors:  G Wang; T J Wilson; Q Jiang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene.

Authors:  G Sisson; J Y Jeong; A Goodwin; L Bryden; N Rossler; S Lim-Morrison; A Raudonikiene; D E Berg; P S Hoffman
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

9.  Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population.

Authors:  Sook-Yin Lui; Khay-Guan Yeoh; Bow Ho
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.

Authors:  Sander J O Veldhuyzen van Zanten; Tassia Kolesnikow; Vincent Leung; Jani L O'Rourke; Adrian Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.